These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 22486311

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.
    Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Wang Q, Costello CE, Zaia J, Seaton BA, Sharon J.
    Immunology; 2013 Nov; 140(3):374-89. PubMed ID: 23844703
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.
    Roche MI, Lu Z, Hui JH, Sharon J.
    Hybridoma (Larchmt); 2011 Feb; 30(1):19-28. PubMed ID: 21466282
    [Abstract] [Full Text] [Related]

  • 8. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.
    Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, Lee KT, Comstock LE, Conlan JW, Rubin EJ, Tzianabos AO, Kasper DL.
    Infect Immun; 2007 May; 75(5):2591-602. PubMed ID: 17296751
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.
    Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL.
    J Infect Dis; 2012 Apr 01; 205(7):1056-65. PubMed ID: 21969334
    [Abstract] [Full Text] [Related]

  • 11. A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.
    Wang Q, Shi X, Leymarie N, Madico G, Sharon J, Costello CE, Zaia J.
    Biochemistry; 2011 Dec 20; 50(50):10941-50. PubMed ID: 22091710
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
    Baron SD, Singh R, Metzger DW.
    Infect Immun; 2007 May 20; 75(5):2152-62. PubMed ID: 17296747
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.
    Lu Z, Roche MI, Hui JH, Unal B, Felgner PL, Gulati S, Madico G, Sharon J.
    Immunol Lett; 2007 Oct 15; 112(2):92-103. PubMed ID: 17764754
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
    Tian D, Uda A, Park ES, Hotta A, Fujita O, Yamada A, Hirayama K, Hotta K, Koyama Y, Azaki M, Morikawa S.
    Microbiol Immunol; 2018 Jan 15; 62(1):24-33. PubMed ID: 29171073
    [Abstract] [Full Text] [Related]

  • 20. Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis.
    Shen H, Chen W, Conlan JW.
    Microb Pathog; 2004 Aug 15; 37(2):107-10. PubMed ID: 15312850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.